Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi polska sp.z.o.o. - manitolis - infuzinis tirpalas - 100 g/1000 ml; 150 g/1000 ml - mannitol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - kvinaprilis/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/12,5 mg; 20 mg/12,5 mg - quinapril and diuretics

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vétoquinol sa - bevandenis torasemidas - sulfonamidams, paprastas, aukštos lubos, diuretikai - Šunys - klinikinių požymių, įskaitant edemą ir efuziją, gydymui, susijusioms su širdies nepakankamumu.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sumar pharma ehf - desmopresinas - poliežuvinės tabletės - 60 µg - desmopressin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sumar pharma ehf - desmopresinas - poliežuvinės tabletės - 240 µg - desmopressin

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozino propanedilo monohidratas - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. be kitų vaistų, skirtų gydyti 2 tipo cukrinis diabetas. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloksetinas - diabetinės neuropatijos - psychoanaleptics, - suaugusiųjų diabetinio periferinio neuropatinio skausmo gydymas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ir 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

egis pharmaceuticals plc - ramiprilis/hidrochlorotiazidas - tabletės - 2,5 mg/12,5 mg; 5 mg/25 mg - ramipril and diuretics

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

accord healthcare b.v. - ciklofosfamidas - milteliai injekciniam ar infuziniam tirpalui - 500 mg - cyclophosphamide